A large portion of the USD 9.2m grant will provide bioanalytical capacity for studies aimed at identifying metabolic pathways and biomarkers to inform novel nutritional, disease-prevention, and disease-treatment interventions for health issues that disproportionately affect women and infants in developing countries.
Sapient's untargeted, high throughput discovery metabolomics platform will be applied to analyze tens of thousands of biosamples collected through programs conducted by Bill and Melinda Gates Foundation grantees in its Global Health Discovery Collaboratory.
In addition to rLC-MS analysis, the new grant will enable Sapient to provide grantees with support for biocomputational analyses and molecule identification of key discovered biomarkers, as well as capacity building for analytical and data handling capabilities among the grantees.
The new grant represents an extension of prior funding awarded to Sapient from the Bill and Melinda Gates Foundation which was used to provide population-scale metabolomics discovery analyses for 27 independent global health discovery and translation projects initiated by the foundation's grantees in the areas of COVID-19, maternal, newborn, and child health, infectious disease, and hypoxia.
Sapient's support in these programs led to key discoveries including identification of novel biomarkers of early-stage disease, biological processes, and protective factors that are being used to develop diagnostic field tests and optimal disease prevention and treatment interventions.
Sapient is an end-to-end biomarker discovery organization dedicated to accelerating the mapping of circulating chemistries in humans through rapid, large-scale small molecule biomarker profiling.
Its platform combines advanced mass spectrometry technologies able to assay >11,000 small molecule factors per biosample biocomputational learning, and a proprietary Human Biology Database with data from several hundred thousand biosamples to discover circulating biomarkers of health, disease, and drug responsiveness at unprecedented speed and scale.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer